Milestones

1. Leading the MS research line of WP6 for the identification of treatment response biomarkers in various autoimmune diseases, within the framework of the European project 3TR - "Taxonomy, Treatment, Targets and Remission: Identification of the Molecular Mechanisms of non-response to Treatments, relapses and remission in Autoimmune Inflammatory Conditions".
2. Identification of immunological mechanisms that play an important role in acute inflammation and neurodegeneration in MS, using advanced cytometry, proteomics, and metabolomics studies, yielding new therapeutic targets: two articles published in Front Immunol (doi: 10.3389/fimmu.2025.1648725 and doi: 10.3389/fimmu.2025.1729500) and one article in Int J Mol Sci (doi: 10.3390/ijms26146898).
3. Publication of a clinical guideline/consensus document, in collaboration with the Spanish Society of Neurology, for the use of sNfL as a biomarker in MS (doi: 10.1016/j.nrl.2025.501928).
4. Implementation in clinical practice of the use of sNfL as a biomarker in MS patients in the Community of Madrid, and of sGFAP at the Ramón y Cajal University Hospital.
5. Establishment of Mautilus Ehealth, a startup born from the MISIÓN IRYCIS 2030 program, to revolutionize MS monitoring with artificial intelligence. EMCare is its main product, a mobile app that passively and non-intrusively monitors physical variables to predict the risk of MS progression, facilitating early detection for neurologists. Renewal of agreements and signing of new contracts with various pharmaceutical companies (Roche Farma, Meck, Novartis, Neuraxpharm, and Bristol Myers Squibb) to quantify sNfL and sGFAP through the SCT "Precision Immunological Markers" led by the group. Initiation of eight new clinical trials.